Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly, significantly diminishing quality of life. Currently, there is no available treatment to reverse retinal degeneration and neuronal loss, prompting a focus on interventions that slow the progression of intermediate AMD and geographic atrophy. Berries are rich in bioactive compounds, including flavonoids, anthocyanins, carotenoids, and resveratrol, known for their antioxidant, anti-inflammatory, and anti-angiogenic properties. Preclinical studies suggest that extracts from various berries, such as aronia, honeysuckle, black currant, goji, and bilberry, can improve retinal health by reducing oxidative stress and inflammation. Although clinical trials are limited, emerging evidence indicates that dietary intake of these compounds may enhance visual function and slow the progression of AMD. This review summarizes findings from both animal studies and clinical trials to identify specific berries that have been validated to prevent or delay AMD progression, as well as those with potential therapeutic value. Furthermore, we examine the key phytochemicals present in these berries, their mechanisms of action on macular degeneration, and their distinct properties for therapeutic application. A deeper understanding of these characteristics could enable the rational appliance of berries, especially wolfberry, and berry-derived components, such as carotenoids and anthocyanins, to optimize better therapeutic outcomes in AMD management.